The effects of boceprevir and telaprevir on the pharmacokinetics of maraviroc: An open-label, fixed-sequence study in healthy volunteers

Journal of Acquired Immune Deficiency Syndromes

Volumn 65, Issue 5, 2014, Pages 564-570

  Vourvahis, Manoli ^a   Plotka, Anna ^a   Kantaridis, Constantino ^a   Fang, Annie ^a   Heera, Jayvant ^a  

^a PFIZER INC   (United States)

Author keywords

Boceprevir; Drug interaction; Maraviroc; Pharmacokinetics; Telaprevir

Indexed keywords

BOCEPREVIR; MARAVIROC; TELAPREVIR;

ABDOMINAL PAIN; ADULT; ANAL COMPLAINT; AREA UNDER THE CURVE; CONFERENCE PAPER; DECREASED APPETITE; DEFECATION HABIT; DIARRHEA; DISEASE SEVERITY; DIZZINESS; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; DYSGEUSIA; FATIGUE; HUMAN; MALE; MAXIMUM PLASMA CONCENTRATION; MEDICATION COMPLIANCE; MONOTHERAPY; MORNING DOSAGE; NORMAL HUMAN; OPEN STUDY; ORTHOSTATIC HYPOTENSION; PARESTHESIA; PATIENT COMPLIANCE; PHASE 1 CLINICAL TRIAL; PLASMA CONCENTRATION-TIME CURVE; PRIORITY JOURNAL; PRURITUS; SIDE EFFECT; SINGLE DRUG DOSE; TIME TO MAXIMUM PLASMA CONCENTRATION;

ADOLESCENT; ADULT; ANTIVIRAL AGENTS; CYCLOHEXANES; HEALTHY VOLUNTEERS; HUMANS; MALE; MIDDLE AGED; OLIGOPEPTIDES; PROLINE; TRIAZOLES; YOUNG ADULT;

EID: 84898013994     PISSN: 15254135     EISSN: 10779450     Source Type: Journal    
DOI: 10.1097/QAI.0000000000000090     Document Type: Conference Paper

References (33)

1. ViiV Healthcare. Selzentry (maraviroc) prescribing information. Available at: Http://www.viivhealthcare.com/;/media/Files/G/GlaxoSmithKline-Plc/pdfs/us- selzentry.pdf. Accessed April 3, 2013
2. ViiV Healthcare. Celsentri (maraviroc) summary of product characteristics. Available at: Http://www.viivhealthcare.com/products/ selzentrycelsentri. aspx#. Accessed April 3, 2013
3. Abel S, Back DJ, Vourvahis M. Maraviroc: Pharmacokinetics and drug interactions. Antivir Ther. 2009;14:607-618
4. Centers for Disease Control and Prevention. HIV and viral hepatitis. Available at: Http://www.cdc.gov/hiv/resources/factsheets/hepatitis.htm. Accessed April 3, 2013
5. Puoti M, Manno D, Nasta P, et al. The burden of HIV and hepatitis C virus coinfection. Curr Opin HIV AIDS. 2007;2:460-465
6. Merck Sharp & Dohme Corp. Victrelis (boceprevir) prescribing information. Available at: Http://www.merck.com/product/usa/pi-circulars/v/ victrelis/victrelis-pi.pdf. Accessed April 3, 2013
7. Merck Sharp & Dohme Ltd. Victrelis (boceprevir) summary of product characteristics. Available at: Http://www.medicines.org.uk/emc/medicine/24768/ SPC/. Accessed April 3, 2013
8. Vertex Pharmaceuticals Inc. Incivek (telaprevir) prescribing information. Available at: Http://pi.vrtx.com/files/uspi-telaprevir.pdf. Accessed April 3, 2013
9. Janssen-Cilag Ltd. Incivo (telaprevir) summary of product characteristics. Available at: Http://www.medicines.org.uk/emc/medicine/25038/ SPC/. Accessed April 3, 2013
10. Brewer E, Felix T, Clarke P, et al. An LC-MS-MS method for quantitative determination of maraviroc (UK-427,857) in human plasma, urine and cerebrospinal fluid. Biomed Chromatogr. 2010; 24:1316-1323
11. Weatherley B, Vourvahis M, McFadyen L. Modeling of maraviroc pharmacokinetics in the presence of atazanavir/ritonavir in healthy volunteers and HIV-1-infected patients. Abstract presented at: 12th International Workshop on Clinical Pharmacology of HIV Therapy; April 13-15, 2011; Miami, FL.
12. U.S. Department of Health and Human Services FaDACfDEaRC. Guidance for Industry: Statistical Approaches to establishing Bioequivalence. Available at: Http://www.fda.gov/downloads/Drugs/Guidances/ucm070244. pdf. Accessed January 2, 2014
13. Garg V, van Heeswijk R, Yang Y, et al. The pharmacokinetic interaction between an oral contraceptive containing ethinyl estradiol and norethindrone and the HCV protease inhibitor telaprevir. J Clin Pharmacol. 2012;52:1574-1583
14. Center for Drug Evaluation and Research. Boceprevir: Application number 202258Orig1s000. Other reviews. Available at: Http://www. accessdata.fda.gov/ drugsatfda-docs/nda/2011/202258Orig1s000OtherR. pdf. Accessed April 4, 2013
15. Center for Drug Evaluation and Research. Telaprevir: Application number 201917Orig1s000. Clinical pharmacology and biopharmaceutics review. Available at: Http://www.accessdata.fda.gov/drugsatfda-docs/nda/2011/ 201917Orig1s000ClinPharmR.pdf. Accessed April 4, 2013
16. Hammond KP, Wolfe P, Burton JR Jr, et al. Pharmacokinetic interaction between boceprevir and etravirine in HIV/HCV seronegative volunteers. J Acquir Immune Defic Syndr. 2013;62:67-73
17. Nasta P, Gatti F, Borghi F, et al. Maraviroc (MVC) reduces liver stiffness (LS) in HIV-hepatitis C (HCV) co-infected patients. Abstract presented at: 6th IAS Conference on HIV Pathogenesis, Treatment and Prevention; July 17-20, 2013; Rome, Italy
18. Siccardi M, DAvolio A, Nozza S, et al. Maraviroc is a substrate for OATP1B1 in vitro and maraviroc plasma concentrations are influenced by SLCO1B1 521 T.C polymorphism. Pharmacogenet Genomics. 2010;20:759-765
19. Vourvahis M, Sanders F, Malarstig A, et al. Impact of genetic variants of OATP1B1 (SLCO1B1) on maraviroc pharmacokinetics. Poster PE6.4 presented at: European AIDS Conference; October 12-15, 2011; Belgrade, Serbia
20. Kunze A, Huwyler J, Camenisch G, et al. Interaction of the antiviral drug telaprevir with renal and hepatic drug transporters. Available at: Biochem. Pharmacol
21. Center for Drug Evaluation and Research. Boceprevir: Application number 202258Orig1s000. Other reviews. Available at: Http://www. accessdata.fda.gov/ drugsatfda-docs/nda/2011/202258orig1s000clinpharmr.pdf. Accessed November 19, 2013
22. Roche Farma SALS. Invirase (saquinavir mesylate) summary of product characteristics. Available at: Http://www.gene.com/download/pdf/Invirase %20PI%20November%202012%20%281%29.pdf. Accessed November 19, 2013
23. Annaert P, Ye ZW, Stieger B, et al. Interaction of HIV protease inhibitors with OATP1B1, 1B3, and 2B1. Xenobiotica. 2010;40:163-176
24. Weatherley B, McFadyen L, Chan PLS, et al. Population pharmacokinetic covariate analysis of maraviroc in Phase 2b/3 studies in treatment experienced (TE) HIV-1 infected subjects on optimized background therapy (OBT). Poster 17a presented at: 9th International Workshop on Clinical Pharmacology of HIV Therapy; April 7-9, 2008; New Orleans, LA.
25. McFadyen L, Jacqmin P, Wade JR, et al. Maraviroc (MVC) exposure- efficacy relationship in treatment-experienced HIV-1-infected patients. Poster P4.1/06 presented at: 11th European AIDS Conference; October 24-27, 2007; Madrid, Spain
26. McFadyen L, Jacqmin P, Weatherley B, et al. Lack of adherence to treatment drives maraviroc exposure response in the MERIT study in treatment naive subjects. Poster presented at: 11th International Workshop on Clinical Pharmacology of HIV Therapy; April 7-9, 2010; Sorrento, Italy
27. Kolwankar D, Vuppalanchi R, Ethell B, et al. Association between nonalcoholic hepatic steatosis and hepatic cytochrome P-450 3A activity. Clin Gastroenterol Hepatol. 2007;5:388-393
28. Donato MT, Lahoz A, Jimenez N, et al. Potential impact of steatosis on cytochrome P450 enzymes of human hepatocytes isolated from fatty liver grafts. Drug Metab Dispos. 2006;34:1556-1562
29. Ohnishi A, Murakami S, Akizuki S, et al. In vivo metabolic activity of CYP2C19 and CYP3A in relation to CYP2C19 genetic polymorphism in chronic liver disease. J Clin Pharmacol. 2005;45: 1221-1229
30. Villeneuve JP, Pichette V. Cytochrome P450 and liver diseases. Curr Drug Metab. 2004;5:273-282
31. Bastien MC, Leblond F, Pichette V, et al. Differential alteration of cytochrome P450 isoenzymes in two experimental models of cirrhosis. Can J Physiol Pharmacol. 2000;78:912-919
32. Peterson TC, Hodgson P, Fernandez-Salguero P, et al. Hepatic fibrosis and cytochrome P450: Experimental models of fibrosis compared to AHR knockout mice. Hepatol Res. 2000;17:112-125
33. Abel S, Davis JD, Ridgway CE, et al. Pharmacokinetics, safety and tolerability of a single oral dose of maraviroc in HIV-negative subjects with mild and moderate hepatic impairment. Antivir Ther. 2009;14: 831-837